GoodGut and the Beth Israel Deaconess Medical Center (BIDMC) in Boston are collaborating on a clinical trial to validate the RAID-CD test for diagnosing inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS). The study is being led by Dr Alan Moss, gastroenterologist at the prestigious centre and associate professor at Harvard Medical School.
Dr Moss has taken an interest in the test being developed by Goodgut due to the contribution it will make to innovating healthcare systems: it is a non-invasive test which for the first time offers a positive diagnosis for IBS and differential diagnosis for IBD. RAID-CD will help to reduce the direct costs generated by the incorrect diagnosis of these bowel diseases, and the waiting time for patients suffering from the diseases. It is also more reliable than current systems as it is based on a specific biomarker in a stool sample.
The BIDMC Inflammatory Bowel Disease Centre is one of the most active in researching these diseases in the United States, while Dr Moss’s translational research group is focused on faecal biomarkers, vitamin D as immunomodulator and intestinal microbiota as therapeutic goal.
In September GoodGut’s researcher Joan Amoedo visited the centre as the company’s representative to monitor the trial and process patient samples.
It is calculated that 50 million people around the world are affected by IBD, Crohn’s disease and ulcerative colitis, with diagnosis tending to be slow and based on vague clinical parameters. IBS meanwhile is one of the 10 most difficult diseases to identity according to Fleming’s list.